Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Delivery systems for antisense oligonucleotides.

C Garcia-Chaumont1, O Seksek, J Grzybowska

  • 1LPBC, CNRS ESA 7033, Université Pierre et Marie Curie, case 138, 4, place Jussieu, 75252 05, Paris cedex, France.

Pharmacology & Therapeutics
|September 29, 2000
PubMed
Summary

Antisense therapy delivery systems are improving, with new methods focusing on cell membrane permeabilization to bypass endosomal entrapment. Future research aims for in vivo efficacy and serum-resistant vectors for oligodeoxyribonucleotides (ODNs).

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Revealing the biomolecular response of glioma cells to helium, carbon and oxygen minibeam radiation therapy using synchrotron-based infrared microspectroscopy.

The Analyst·2026
Same author

Correction: Synchrotron-based infrared microspectroscopy unveils the biomolecular response of healthy and tumour cell lines to neon minibeam radiation therapy.

The Analyst·2025
Same author

Synchrotron-based infrared microspectroscopy unveils the biomolecular response of healthy and tumour cell lines to neon minibeam radiation therapy.

The Analyst·2024
Same author

Study of the intracellular nanoparticle-based radiosensitization mechanisms in F98 glioma cells treated with charged particle therapy through synchrotron-based infrared microspectroscopy.

The Analyst·2020
Same author

A synchrotron-based infrared microspectroscopy study on the cellular response induced by gold nanoparticles combined with X-ray irradiations on F98 and U87-MG glioma cell lines.

The Analyst·2019
Same author

Nutritional factors and progenitor cell differentiation.

Genes & nutrition·2008

Area of Science:

  • Biotechnology
  • Molecular Biology
  • Drug Delivery Systems

Background:

  • Antisense therapy relies on delivering oligodeoxyribonucleotides (ODNs) into cells for efficacy.
  • Current delivery vectors often utilize endocytosis, which can trap ODNs within endosomal compartments, limiting their therapeutic potential.
  • Overcoming endosomal entrapment is crucial for enhancing antisense therapy effectiveness.

Purpose of the Study:

  • To review and highlight advancements in oligodeoxyribonucleotide (ODN) delivery systems.
  • To discuss strategies for overcoming endosomal entrapment of ODNs.
  • To explore novel vector designs for improved in vitro and in vivo delivery.

Main Methods:

  • Review of existing and emerging oligodeoxyribonucleotide (ODN) delivery systems.

Related Experiment Videos

  • Categorization of vectors based on cellular uptake mechanisms (endocytosis vs. membrane permeabilization).
  • Discussion of challenges and requirements for in vivo application.

    • Main Results:

    • Particulate systems (liposomes, polyelectrolytes) and receptor-targeted systems primarily use endocytosis for ODN delivery.
    • A new class of vectors, including peptides and polyene antibiotic derivatives, facilitates ODN entry via passive plasma membrane permeabilization.
    • In vivo application of ODN delivery systems remains limited, with serum sensitivity being a key challenge.

    Conclusions:

    • Developing strategies to escape endosomal compartments is essential for improving ODN delivery.
    • Vectors that passively permeabilize cell membranes offer a promising alternative to endocytosis-dependent systems.
    • Future advancements require the development of serum-insensitive vectors for successful in vivo antisense therapy.